Kidney Cancer Diagnostics and Therapeutics Market Report 2025

The kidney cancer diagnostics and therapeutics market size has grown strongly in recent years. It will grow from $4.1 billion in 2024 to $4.32 billion in 2025 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to research on molecular biology, clinical trials and drug development, surgical innovations, genetic discoveries, healthcare access improvements.

The kidney cancer diagnostics and therapeutics market size is expected to see strong growth in the next few years. It will grow to $5.68 billion in 2029 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to biomarker research, genomic sequencing advances, telemedicine and remote consultations, precision medicine advancements, rapid diagnostic technologies. Major trends in the forecast period include palliative care integration, long-term survivorship care, nutrition and lifestyle intervention, expanded role of radiomics, liquid biopsies adoption.

The anticipated rise in kidney cancer prevalence is poised to be a driving force behind the expansion of the kidney cancer diagnostics and therapeutics market. Kidney cancer, characterized by abnormal changes in normal kidney cells leading to uncontrolled growth and the formation of renal cortical tumors, necessitates effective diagnostics and therapeutics for optimal disease management. These components offer several advantages, including early detection, precise diagnosis, personalized medicine, and treatment monitoring. As per the American Society of Clinical Oncology (ASCO) in March 2023, it is estimated that 81,800 individuals in the United States will be diagnosed with kidney cancer in 2023, with a global impact of 431,288 cases in 2020. Consequently, the increasing prevalence of kidney cancer is expected to foster the growth of the kidney cancer diagnostics and therapeutics market.

The anticipated increase in healthcare spending is expected to drive the growth of the kidney cancer diagnostics and therapeutics market in the future. Healthcare spending encompasses the total financial resources allocated to the healthcare sector within a specific region, country, or organization. Investing in kidney cancer diagnostics and therapeutics is crucial for early detection, effective treatment, and improved patient outcomes. This investment addresses the diagnostic needs for timely intervention and the therapeutic requirements for optimal care, ultimately contributing to better overall health and reducing long-term healthcare costs. For instance, in March 2022, the Centers for Medicare & Medicaid Services, a US-based Department of Health and Human Services department, published the 2021-2030 National Health Expenditure (NHE) report, predicting an average annual increase in national health spending of 5.1% from 2021 to 2030, with total spending expected to reach approximately $6.8 trillion by 2030. Thus, the rise in healthcare spending is driving the growth of the kidney cancer diagnostics and therapeutics market.

Major companies in the kidney cancer diagnostics and therapeutics market are concentrating on the development of advanced treatments for renal cell carcinoma (RCC) to enhance patient outcomes and offer innovative treatment options tailored to the unique needs of individuals diagnosed with this complex disease. Research focused on renal cell carcinoma (RCC) is vital for the advancement of kidney cancer diagnostics and therapeutics, as it fosters the creation of new diagnostic techniques and targeted therapies that facilitate early diagnosis and personalized treatment plans for patients. For example, in December 2023, Merck, a US-based pharmaceutical company, introduced welireg (belzutifan), the first hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor approved for adult patients with advanced renal cell carcinoma (RCC) following previous treatments with PD-1 or PD-L1 inhibitors and VEGF-TKIs. This groundbreaking therapeutic class offers notable advantages, including enhanced progression-free survival and higher response rates compared to everolimus. The approval of WELIREG signifies a significant advancement in the kidney cancer diagnostics and therapeutics market, providing renewed hope for patients facing disease progression.

Major companies in the kidney cancer diagnostics and therapeutics market are focusing on adapting clinical trial collaborations to enhance research capabilities, speed up the development of innovative treatments, and improve patient access to cutting-edge therapies through shared expertise and resources. These collaborations are crucial for advancing kidney cancer diagnostics and therapeutics, as they combine expertise, resources, and data, thereby accelerating the creation of novel treatments and diagnostic tools, and enhancing patient outcomes through more effective therapies. For instance, in December 2023, Exelixis, Inc., a US-based company, announced a clinical trial collaboration with Arcus Biosciences Inc., also based in the US, to evaluate Zanzalintinib in combination with AB521 for patients with advanced renal cell carcinoma (RCC). This clinical trial, designated as STELLAR-009, is a Phase 1b/2 study aimed at assessing the safety, tolerability, and preliminary efficacy of Zanzalintinib when used alongside AB521. The trial will also evaluate the pharmacokinetics (PK) of these drugs in patients with advanced clear cell renal cell carcinoma (ccRCC) and other solid tumors.

In May 2023, Telix Pharmaceuticals Limited, an Australia-based biotechnology research firm, acquired QSAM Biosciences, Inc. for an undisclosed amount. This acquisition is intended to strengthen Telix's portfolio in the development of targeted radiopharmaceuticals, especially for cancer treatment. By incorporating QSAM's expertise and technologies, Telix aims to accelerate the advancement of its innovative therapies and expand its market presence in the precision medicine sector. QSAM Biosciences Inc. is a biotechnology research company based in the US.

Major companies operating in the kidney cancer diagnostics and therapeutics market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A, Bristol-Myers Squibb Pharmaceuticals Limited, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Amgen Inc., Siemens Healthcare GmbH, Laboratory Corporation of America Holdings, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Eisai Co. Ltd., Illumina Inc., PerkinElmer Inc., Ipsen S.A, Bio-Rad Laboratories Inc., QIAGEN NV, Exelixis Inc., Myriad Genetics Inc., Invitae Corporation, Guardant Health Inc., GeneDx LLC, CD Genomics, Genpath Life Sciences Private Limited.

North America was the largest region in the kidney cancer diagnostics and therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney cancer diagnostics and therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the kidney cancer diagnostics and therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Kidney cancer diagnostics and therapeutics encompass methods and treatments utilized for diagnosing and managing kidney cancer, specifically renal cell carcinoma. The primary objectives of these approaches are to detect the presence of kidney cancer, assess its stage and extent, and offer appropriate treatment options to effectively manage the disease.

The main types of kidney cancer include clear cell RCC, papillary RCC, chromophobe RCC, urothelial carcinoma, transitional cell carcinoma, and others. Clear-cell renal cell carcinoma (RCC) is the predominant type, accounting for the majority of kidney cancer cases. RCC is further categorized into various subtypes based on the microscopic appearance of cancer cells. Kidney cancer diagnostics and therapeutics play a crucial role in managing clear cell renal cell carcinoma (RCC), the most prevalent subtype of kidney cancer. Treatment involves the use of components such as drugs and diagnostics, with diagnostics including biopsy, CT scan, nephro-ureteroscopy, intravenous pyelogram, and ultrasound. Therapies for kidney cancer include targeted therapy, immunotherapy, and chemotherapy. The main end-users of these diagnostics and therapeutics are hospitals, pharmaceutical labs, and genomic laboratories.

The kidney cancer diagnostics and therapeutics market research report is one of a series of new reports that provides kidney cancer diagnostics and therapeutics market statistics, including kidney cancer diagnostics and therapeutics industry global market size, regional shares, competitors with a kidney cancer diagnostics and therapeutics market share, detailed kidney cancer diagnostics and therapeutics market segments, kidney cancer diagnostics and therapeutics market trends and opportunities, and any further data you may need to thrive in the kidney cancer diagnostics and therapeutics industry. This kidney cancer diagnostics and therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The kidney cancer diagnostics and therapeutics market consists of revenues earned by entities by providing kidney cancer diagnostics and therapeutics services such as screening and diagnosis, treatment and therapeutics, radiation therapy, chemotherapy, and surgical interventions services. The market value includes the value of related goods sold by the service provider or included within the service offering. The kidney cancer diagnostics and therapeutics market also includes sales of imaging equipment, biopsy tools, surgical instruments, and supportive care products which are used in providing kidney cancer diagnostics and therapeutics services. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.